Full Press Release Details
EIP Pharma Announces Publication of Preclinical Results Demonstrating Potential of Neflamapimod to Promote Functional Recovery after Ischemic Stroke.
CRVO
EIP Pharma Announces Publication of Preclinical Results Demonstrating Potential of Neflamapimod to Promote Functional Recovery after Ischemic Stroke
Key Takeaway: EIP Pharma Announces Publication of Preclinical Results Demonstrating Potential of Neflamapimod to Promote Functional Recovery after Ischemic Stroke
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke